The University Hospital of Salamanca is the newest costumer in Spain that will be using suPARnostic® TurbiLatex in clinical routine.

The hospital’s decision to implement our product to improve their triage follows a process of pilot use of suPARnostic® TurbiLatex and is based on underlying data from international use as well as experience elsewhere on the Spanish market.

This is already the fourth Spanish hospital that has adopted the suPARnostic® TurbiLatex product this year.

The University Hospital of Salamanca is affiliated with the oldest university in Spain and is generally highly regarded for its clinical research. It is furthermore a leading hospital in the region Castilla y León, and has an uptake population of around 300,000 inhabitants and 900 beds.

Our product will not only be used in the Emergency Department, but also with regards to COVID-19 patients currently seeking treatment at the hospital.

Jakob Knudsen, Chief Executive Officer of ViroGates, says: ”We are really excited to supply our products for this leading regional hospital in Spain. The University Hospital in Salamanca has been using our product now in a pilot phase to get acquainted with the use, and has now expeditely decided to implement our product in clinical routine. The Hospital has made the first order today in connection with the official decision to implement suPARnostic® TurbiLatex in clinical routine.

The implementation is based on general triage of patients in the emergency department, but we have learned that the decision to implement our product is also driven by the large amounts of patients with positive Covid-19 tests seeking treatment at the Hospital currently.”